These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35419830)

  • 21. A perfect storm: Tumor lysis syndrome with rasburicase-induced methemoglobinemia in a G6PD deficient adult.
    Montgomery KW; Booth GS
    J Clin Apher; 2017 Feb; 32(1):62-63. PubMed ID: 27119769
    [No Abstract]   [Full Text] [Related]  

  • 22. Rasburicase-induced hemolytic anemia in previously undiagnosed G6PD deficiency.
    Ferguson D; Kovach AE
    Blood; 2018 Aug; 132(6):673. PubMed ID: 30093385
    [No Abstract]   [Full Text] [Related]  

  • 23. Perioperative management of the glucose-6-phosphate dehydrogenase deficient patient: a review of literature.
    Elyassi AR; Rowshan HH
    Anesth Prog; 2009; 56(3):86-91. PubMed ID: 19769422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome.
    Brant JM
    Clin J Oncol Nurs; 2002; 6(1):12-6. PubMed ID: 11842483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced germ cell tumors and chemotherapy in G6PD deficient patients: Yes to chemotherapy but no to rasburicase and some premedications.
    Gazouli I; Baltogiannis D; Ntellas P; Smaragdi Vlachou M; Tagkas C; Champilomatis I; Kampletsas Ε; Tolia M; Mauri D
    J BUON; 2021; 26(4):1642-1646. PubMed ID: 34565030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype.
    Gammal RS; Pirmohamed M; Somogyi AA; Morris SA; Formea CM; Elchynski AL; Oshikoya KA; McLeod HL; Haidar CE; Whirl-Carrillo M; Klein TE; Caudle KE; Relling MV
    Clin Pharmacol Ther; 2023 May; 113(5):973-985. PubMed ID: 36049896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
    Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucose-6-phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks.
    Francis RO; Jhang JS; Pham HP; Hod EA; Zimring JC; Spitalnik SL
    Vox Sang; 2013 Nov; 105(4):271-82. PubMed ID: 23815264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
    Patel KS; Lau JE; Zembillas AS; Gallagher EM
    J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
    Gopakumar KG; Thankamony P; Seetharam S; P K
    Pediatr Hematol Oncol; 2017 May; 34(4):206-211. PubMed ID: 28872997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum microRNAs as new biomarkers for detecting subclinical hemolysis in the nonacute phase of G6PD deficiency.
    Boonpeng K; Shibuta T; Hirooka Y; Kulkeaw K; Palasuwan D; Umemura T
    Sci Rep; 2024 Jul; 14(1):16029. PubMed ID: 38992151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
    Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
    Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
    Roberts DA; Freed JA
    Eur J Haematol; 2015 Jan; 94(1):83-5. PubMed ID: 24750455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
    Khalighi PR; Martens KL; White AA; Li S; Silgard E; Frieze D; Garcia DA; Li A
    J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
    Boutin A; Blackman A; O'Sullivan DM; Forcello N
    J Oncol Pharm Pract; 2019 Apr; 25(3):577-583. PubMed ID: 29320954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Hydroxychloroquine use and Hemolytic Anemia in Patients With Low Levels of Glucose-6-Phosphate Dehydrogenase.
    Ramirez de Oleo IE; Mejia Saldarriaga M; Johnson BK
    J Clin Rheumatol; 2022 Jan; 28(1):e23-e25. PubMed ID: 32956151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
    Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
    Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rasburicase-induced methaemoglobinaemia and G6PD deficiency in an unusual suspect.
    Oluwasanjo A; Alese O; Swierczynski S; Forman D
    Br J Haematol; 2015 Sep; 170(5):595. PubMed ID: 26033222
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.